Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial

Area of Science:

• Pediatric Emergency Medicine
• Respiratory Physiology
• Pharmacology

Background:

• Bronchiolitis is a common viral respiratory infection in infants.
• Current treatments include supportive care and bronchodilators, with variable efficacy.
• Heliox (helium-oxygen) therapy is explored for its potential to improve airflow in obstructive airway diseases.

Purpose of the Study:

• To compare the effectiveness of nebulized racemic epinephrine with helium-oxygen (heliox) vs. oxygen via high-flow nasal cannula (HFNC) in treating bronchiolitis.
• To evaluate the impact of heliox inhalation therapy on clinical scores in infants with bronchiolitis.

Main Methods:

• Prospective, randomized, single-blind controlled trial in a pediatric emergency department.
• Infants (2-12 months) with bronchiolitis (Modified Wood's Clinical Asthma Score [M-WCAS] ≥3) received albuterol, then nebulized racemic epinephrine.
• Patients were randomized to receive heliox or oxygen via HFNC, with potential for a second nebulization dose.

Main Results:

• The heliox group showed a significantly greater mean improvement in M-WCAS (1.84) compared to the oxygen group (0.31) at 240 minutes or discharge (P < .001).
• Significant improvements in M-WCAS were observed in the heliox group at 60, 120, 180, and 240 minutes compared to the oxygen group.
• 69 infants were enrolled; 34 received heliox and 35 received oxygen therapy.

Conclusions:

• Heliox therapy, combined with nebulized racemic epinephrine and HFNC, demonstrated superior clinical improvement in infants with bronchiolitis compared to oxygen therapy.
• This heliox-based approach offers a potentially more effective treatment strategy for moderate to severe bronchiolitis.
• The study provides evidence supporting the use of heliox in managing pediatric bronchiolitis.